Sex Differences in Circulating Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease

Anurag Mehta, MD; Shivang R. Desai, MD; Yi-An Ko, PhD; Chang Liu, MPH; Devinder S. Dhindsa, MD; Aditi Nayak, MD; Ananya Hooda, MBBS; Mohamed A. Martini, MD; Kiran Ejaz, MD; Laurence S. Sperling, MD; Jochen Reiser, MD, PhD; Salim S. Hayek, MD; Arshed A. Quyyumi, MD

**Background**—Women have higher circulating levels of soluble urokinase-type plasminogen activator receptor (suPAR), and elevated suPAR is associated with cardiovascular risk. The independent association of sex with suPAR and the impact of sex on its association with cardiovascular risk are unknown.

**Methods and Results**—Plasma suPAR was measured using ELISA in 2 cohorts of 666 asymptomatic individuals (49 years, 65% women) and 4184 patients with coronary artery disease (63 years, 37% women). Independent association of sex with suPAR was studied using linear regression models adjusted for demographics, risk factors, and visceral adiposity in asymptomatic participants. Impact of sex on association of suPAR with all-cause mortality was studied in patients with coronary artery disease using multivariable-adjusted Cox models. Sex-specific suPAR cutoffs for predicting all-cause mortality were calculated. Asymptomatic women had 10% higher suPAR compared with men after adjusting for confounders, and visceral adiposity partly accounted for this association. Over a median follow-up of 5.2 years, 795 deaths were recorded in patients with coronary artery disease. Log2-transformed suPAR was independently associated with mortality (hazard ratio per 1-SD 1.72, 95% CI 1.60–1.85) and an interaction with sex was noted ($P=0.005$). Association of suPAR with mortality was slightly weaker in women (hazard ratio 1.61, 95% CI 1.41–1.83) compared with men (hazard ratio 1.83, 95% CI 1.67–2.00). However, using sex-specific suPAR cut-offs (4392 pg/mL for women and 3187 pg/mL for men), a similar mortality incidence was observed for both sexes (38.5% and 35.5%, respectively, $P=0.3$).

**Conclusions**—Women have 10% higher plasma suPAR levels compared with men. Elevated sex-specific plasma suPAR levels are equally predictive of risk of adverse events in both sexes. (**J Am Heart Assoc.** 2020;9:e015457. DOI: 10.1161/JAHA.119.015457.)

**Key Words:** biomarkers • coronary artery disease • outcomes • sex differences • SuPAR

Coronary artery disease (CAD) is the leading cause of mortality worldwide. The existing cardiovascular risk assessment paradigms in the general population and among those with CAD involve ascertainment of high-risk clinical characteristics that are associated with adverse outcomes. These approaches are imperfect and do not capture the effect of subclinical inflammation and immune activation that are integral to the pathobiology of atherosclerosis.

In this context, novel circulating protein-based, inflammatory biomarkers hold a promising role for stratifying...
cardiovascular risk. Soluble urokinase-type plasminogen activator receptor (suPAR), a marker of systemic immune activation, inflammation, and thrombogenesis, is one such promising biomarker. SuPAR is typically cleaved off the plasma membrane by the enzymatic processing of the glycosyl-phosphatidylinositol-anchor in podocytes, immature myeloid cells, vascular endothelial cells, and activated T-lymphocytes. Both membrane-bound and soluble forms regulate cell adhesion and migration by interacting directly with integrins, and the soluble form’s chemotactic properties play a role in recruiting granulocytes, mobilizing hematopoietic stem cells, and in podocyte detachment. Elevated circulating suPAR levels are associated with several measures of CAD; it is inversely correlated with coronary flow reserve, is associated with presence of coronary calcium, with CAD severity, and with increased risk of future cardiovascular events and mortality. Moreover, unlike other biomarkers, circulating suPAR levels remain stable during acute coronary syndromes and after surgery, making it a possibly more reliable biomarker in these populations.

Similar to hsCRP (high-sensitivity C-reactive protein), circulating suPAR levels are known to be higher among women compared with men, but the independent association of sex with suPAR is unclear and so are the reasons for these observed sex-based differences. Furthermore, it is unknown whether the association of suPAR with adverse outcomes is influenced by sex. Therefore in this report we have (1) investigated the relationship between suPAR and sex in a cohort of individuals with and without CAD; (2) explored whether the differences in suPAR levels are secondary to sex-based differences in fat mass, fat distribution, or sex hormones; and (3) evaluated the impact of sex on the association of suPAR with adverse outcomes in a cohort of patients with established CAD.

Methods

Study Population

The subjects analyzed in this study were participants of the Emory Center for Health Discovery and Wellbeing (CHDWB) cohort and the Emory Cardiovascular Biobank (EmCAB) cohort. The study designs for CHDWB and EmCAB cohorts have been previously published, and the study population is described in Data S1. Our analysis includes 666 participants of CHDWB cohort and 4184 participants of the EmCAB cohort. Both studies were approved by the institutional review board at Emory University and study protocols comply with the Declaration of Helsinki. All participants provided written informed consent at the time of enrollment. The data that support the findings of this study are available from the corresponding author upon reasonable request.

Plasma suPAR Measurement

Plasma levels of suPAR were measured with the suPARnostic ELISA assay (ViroGates, Copenhagen, Denmark), which has a lower limit of detection of 100 pg per milliliter and intra- and interassay variations of 2.75% and 9.17%, respectively.

Adverse Outcomes

Participants of the EmCAB cohort were prospectively followed for the primary outcome of all-cause mortality and the secondary outcome of a composite of cardiovascular death/nonfatal myocardial infarction (MI). Follow-up data were obtained by annual phone contact, electronic medical record review, and data from the Social Security death index and state records. The cause of death was determined from medical record review or by direct contact with the participants’ family member(s). Cardiovascular death and nonfatal MI events were adjudicated by 2 cardiologists blinded to study data. Cardiovascular death was defined as death attributable to an ischemic cardiovascular cause such as fatal MI, stroke, or sudden death secondary to a presumed cardiovascular cause in this high-risk population. Nonfatal MI events were adjudicated using the third universal definition of MI.

Statistical Analysis

Baseline characteristics of participants were stratified by sex in both cohorts and are reported as number (proportion) for categorical variables and means (standard deviation) or
Sex Differences in suPAR
Mehta et al

medians [25th percentile–75th percentile] for continuous variables, depending on distribution. Differences between women and men were assessed using \( \chi^2 \) test for categorical variables and the unpaired t test or Mann–Whitney U test for continuous variables.

Plasma suPAR levels in both cohorts were highly right-skewed and were log2-transformed to achieve normality. The independent association of sex with suPAR levels among asymptomatic participants of the CHDWB cohort was determined using linear regression models that were sequentially adjusted for cardiovascular risk factors (Model 1—age, race, diabetes mellitus, current smoking, antihypertensive medication use, systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, statin use, estimated glomerular filtration rate [eGFR], and body mass index), hsCRP (Model 2), and visceral fat measures of total body fat and android-gynoid fat ratio (Model 3). A similar analysis was conducted in the EmCAB cohort, following which the independent predictors of suPAR levels were determined separately in women and men of both cohorts using linear regression models.

Cox proportional hazards regression models were used to investigate the relationship of plasma suPAR levels with all-cause mortality and cardiovascular death/MI among participants of the EmCAB cohort. Plasma suPAR level was the independent variable and was analyzed as continuous (log2-transformed) and categorical (median and quartile level in entire cohort) to study the association with outcomes. Cox models were adjusted for sex, age, race, diabetes mellitus, current smoking, hypertension, body mass index, eGFR, history of CABG, heart failure, peripheral artery disease, acute MI at enrollment, revascularization at enrollment, and cardiovascular medication use (angiotensin-converting enzyme inhibitor or angiotensin-II receptor blocker, aspirin, \( \beta \)-blocker, clopidogrel, and statin). The multiplicative interaction between suPAR levels and sex was examined to test whether the association of suPAR with outcomes depended on sex, and subsequent Cox models were stratified by sex.

The cumulative incidence of all-cause mortality and cardiovascular death/nonfatal MI was plotted across sex-specific deciles of plasma suPAR levels. Lastly, a sex-specific suPAR cutoff for all-cause mortality and cardiovascular death/nonfatal MI was identified based on the maximum likelihood for predicting the respective outcome. To calculate the sex-specific cutoffs, a univariate Cox model was used to calculate the partial likelihood of mortality among women and men. A cutoff that gave the maximum likelihood among all possible cutoffs was then considered to be the optimal sex-specific cut point. Subsequently, suPAR was dichotomized using the candidate cutoff and patients were categorized to either a low- or high-risk category. To minimize the effect of potential data perturbation on the selected optimal cutoff, 500 bootstrap replicates were utilized, and the bootstrap bias corrected estimate was used as the final optimal sex-specific cutoff. Kaplan–Meier curves were used to visualize the survival of EmCAB participants above and below the sex-specific thresholds.

All analyses were performed using IBM SPSS Statistics Version 25 (Armonk, NY) and R version 3.5.1 (R Foundation for statistical computing, Vienna, Austria). Two-tailed \( P<0.05 \) were considered statistically significant.

Results

Baseline Characteristics

The baseline characteristics for CHDWB and EmCAB participants are depicted in Table 1 and Table S1, respectively. In the CHDWB cohort, women were younger, more frequently black, had lower blood pressure and triglyceride levels, and higher total cholesterol, high-density lipoprotein cholesterol, eGFR, and hsCRP levels as compared with men (Table 1). Despite having a similar mean body mass index, women had a significantly higher total fat mass and a lower android-to-gynoid fat ratio (Table 1). Notably, plasma suPAR levels in women were 12.6% higher compared with men.

In the larger EmCAB cohort, women were older, more frequently black, had higher body mass index, and hsCRP level, lower eGFR, and lower prevalence of prior CABG, revascularization at enrollment, and cardiovascular medication use as compared with men (Table S1). Plasma suPAR levels in women with CAD were 17.5% higher. Furthermore, median suPAR levels among EmCAB participants (2930–3929 pg/mL) were significantly higher than in the asymptomatic CHDWB cohort (2543 [2087–3018] pg/mL) (\( P<0.001 \)).

Association of Sex With Plasma suPAR Levels

The impact of sex on suPAR levels in the CHDWB cohort was studied using 4 separate models with stepwise adjustment for covariates (Table 2). After adjustment for cardiovascular risk factors (Model 1) and hsCRP levels (Model 2), suPAR levels were noted to be 16.2% higher (\( P<0.001 \)) in women compared with men (Table 2). To address whether body fat mass or distribution was contributing to this relationship, total body fat and android-gynoid fat ratio were added as covariates in Model 3. The relationship of sex with suPAR was attenuated after controlling for visceral fat measures and women had 10% higher levels (\( P=0.005 \)) as compared with men (Table 2). A similar analysis performed in the EmCAB cohort revealed that sex was an independent predictor of suPAR levels and women with CAD had 11.7% higher levels after adjustment, compared with men (Table S2).

DOI: 10.1161/JAHA.119.015457
We stratified both cohorts by sex and evaluated the sex-specific independent predictors of plasma suPAR levels (Tables S3 and S4). Among female participants in the CHDWB cohort, diabetes mellitus and body fat correlated positively with suPAR levels, while increasing eGFR, high-density lipoprotein, and android-gynoid fat ratio were inversely correlated (Table S3). Age was a predictor in men, while statin use correlated negatively with suPAR levels (Table S3). Importantly, estradiol levels in women and total testosterone levels in men were not associated with suPAR (Table S3).

Among participants of the EmCAB cohort, diabetes mellitus, current smoking, heart failure, peripheral artery disease, and hsCRP levels correlated positively with suPAR levels in both men and women, with eGFR and statin use exhibiting a negative correlation (Table S3).

### Association of suPAR With Adverse Outcomes and the Impact of Sex
Participants in the EmCAB cohort were followed for a median duration of 5.2 [2.1–6.9] years, during which 795 all-cause deaths (301 in women and 494 in men) and 604 cardiovascular death/MI (226 in women and 378 in men) events were recorded. Plasma suPAR was stratified by median (2930 pg/mL) and quartile (2275, 2930, and 3929 pg/mL) levels in the overall EmCAB cohort. The association of continuous and categorical suPAR levels with all-cause mortality and cardiovascular death/MI was assessed using multivariable-adjusted Cox models, and the hazard ratios for these associations are depicted in Table 3. High suPAR (1-SD increase in log2-transformed level) in the overall cohort was independently associated with a nearly 1.7-fold increased risk of adverse outcomes. This association was not attenuated after further adjustment for hsCRP. Both high suPAR (hazard ratio 1.81 [95% CI 1.66–1.98] and 1.58 [95% CI 1.43–1.76] for all-cause mortality and cardiovascular death/nonfatal MI, respectively) and high hsCRP (1-SD increase in log2-transformed level) were independently associated with adverse outcomes [hazard ratio 1.19 [95% CI 1.09–1.30] and 1.20 [95% CI 1.08–1.33] for all-cause mortality and cardiovascular death/nonfatal MI, respectively].

### Table 1. Baseline Characteristics of CHDWB Participants Overall and Stratified by Sex

| Participant Characteristics | Overall (n=666) | Women (n=436) | Men (n=230) | P Value |
|----------------------------|----------------|--------------|------------|---------|
| Age, y (SD)                | 48.7 (10.9)    | 48.0 (10.2)  | 50.0 (12.0)| 0.014   |
| Black race (%)             | 153 (23.0)     | 133 (30.5)   | 20 (8.7)   | <0.001  |
| Diabetes mellitus (%)      | 75 (11.3)      | 53 (12.2)    | 22 (9.6)   | 0.367   |
| Antihypertensive use (%)   | 152 (22.8)     | 99 (22.7)    | 53 (23.0)  | 0.923   |
| Systolic blood pressure, mm Hg (SD) | 120.8 (15.9) | 119.8 (16.7) | 122.9 (14.0) | 0.002   |
| Diastolic blood pressure, mm Hg (SD) | 76.3 (10.9) | 74.7 (10.7) | 79.1 (10.8) | <0.001  |
| Current smoking (%)        | 39 (5.9)       | 20 (4.6)     | 19 (8.3)   | 0.081   |
| Total cholesterol, mg/dL   | 192.0 [169.0, 218.0] | 195.0 [172.3, 219.0] | 189.5 [164.8, 213.3] | 0.008   |
| High-density lipoprotein cholesterol, mg/dL | 61.0 [50.0, 75.0] | 67.0 [54.0, 81.0] | 51.0 [44.0, 61.0] | <0.001  |
| Triglycerides, mg/dL       | 86.0 [65.0, 121.0] | 80.0 [62.3, 108.0] | 100.0 [74.0, 147.0] | <0.001  |
| Low-density lipoprotein cholesterol, mg/dL (SD) | 110.5 (31.6) | 109.8 (32.5) | 111.9 (29.8) | 0.233   |
| eGFR, mL/min per 1.73 m² (SD) | 96.0 (15.8) | 97.2 (16.4) | 93.7 (14.3) | 0.002   |
| Body mass index, kg/m² (SD) | 27.9 (6.4) | 28.2 (7.4) | 27.3 (4.0) | 0.434   |
| Body fat, lb*              | 59.6 [45.1, 78.4] | 62.4 [46.2, 84.1] | 53.4 [43.4, 68.1] | <0.001  |
| Android-to-gynoid fat ratio (SD)* | 0.47 [0.35, 0.62] | 0.40 [0.31, 0.50] | 0.64 [0.53, 0.74] | <0.001  |
| Statin use (%)             | 107 (16.1)     | 39 (8.9)     | 68 (29.6)  | <0.001  |
| hsCRP, mg/L*               | 1.5 [0.5, 3.6] | 1.8 [0.5, 4.2] | 1.0 [0.5, 1.9] | <0.001  |
| suPAR, pg/mL*              | 2543 [2087–3018] | 2619 [2193–3089] | 2378 [1937–2743] | <0.001  |

Continuous variables are presented as mean (SD) or median [25–75th percentile] and categorical variables are presented as count (proportion). CHDWB indicates Emory Center for Health Discovery and Wellbeing; eGFR, estimated glomerular filtration rate; hsCRP, high-sensitivity C-reactive protein; suPAR, soluble urokinase-type plasminogen activator receptor.

*Visceral adiposity measures and biomarkers reported as medians with interquartile ranges. Visceral adiposity measured in 623 participants (407 women, 216 men) and high-sensitivity CRP in 596 participants (393 women, 203 men).

DOI: 10.1161/JAHA.119.015457
Sex Differences in suPAR
Mehta et al

3-fold increase in the risk of adverse outcomes, and a level in the highest quartile was associated with a 3- to 4-fold increase in risk compared with those in the lowest quartile (Table 3). Interestingly, we observed a strong multiplicative interaction between sex and both suPAR categories for all-cause mortality risk ($P$-interactions $= 0.005, 0.007, and 0.001$ for log$_2$-transformed, median, and quartile analyses, respectively). In sex-stratified analyses, the strength of the association between suPAR levels and outcomes was consistently higher among men as compared with women (Table 3).

In order to identify sex-specific optimal cut-offs for the association of suPAR levels with adverse outcomes, women and men were stratified by sex-specific suPAR deciles. The cumulative incidence of all-cause mortality and cardiovascular death/MI across sex-specific suPAR deciles is depicted in Figure 1A and 1B. Overall, the incidence of both adverse outcomes increased across sex-specific suPAR deciles, but the progressive increase in adverse events in women occurred among those above the fifth decile (>$3059$ pg/mL), whereas in men, the increase in risk began at levels above the sixth decile (>$2918$ pg/mL) (Figure 1A and 1B). The incidence of adverse events among both men and women was similar at the highest sex-specific suPAR levels (deciles 9 and 10), suggesting the potential utility of creating sex-specific suPAR cutoffs for predicting outcomes.

The sex-specific suPAR cutoffs for all-cause mortality were $4392$ pg/mL for women (76th percentile) and $3187$ pg/mL for men (64th percentile). The corresponding cutoffs for cardiovascular death/MI were $3888$ pg/mL for women (67th percentile) and $2941$ pg/mL for men (56th percentile).

### Table 2. Independent Association of Female Sex With Plasma suPAR Levels Among CHDWB Participants

| Model | Estimate (95% CI) | $P$ Value |
|-------|------------------|-----------|
| Unadjusted | 12.6% (7.7%, 17.7%) | $<0.001$ |
| Model 1$^*$ | 16.0% (10.2%, 22.1%) | $<0.001$ |
| Model 2$^T$ | 16.2% (10.2%, 22.4%) | $<0.001$ |
| Model 3$^C$ | 10.4% (3.0%, 18.3%) | 0.005 |

CHDWB indicates Emory Center for Health Discovery and Wellbeing; suPAR, soluble urokinase-type plasminogen activator receptor.

$^*$Adjusted for covariates including age, race, diabetes mellitus, smoking, antihypertensive use, systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, statin use, estimated glomerular filtration rate, and body mass index. Total cholesterol, high-density lipoprotein, and body mass index were log-transformed.

$^C$Model 3 adjusted for the covariates included in Model 2 as well as log-transformed body fat mass and android-to-gynoid fat ratio.

$^T$Model 2 adjusted for covariates included in Model 1 and log-transformed high-sensitivity C-reactive protein.

### Table 3. Association of Plasma suPAR With Adverse Outcomes in EmCAB Participants

|                | Overall HR (95% CI) | $P$ Value | Women HR (95% CI) | $P$ Value | Men HR (95% CI) | $P$ Value |
|----------------|---------------------|-----------|------------------|-----------|----------------|-----------|
| **All-cause mortality**$^*$ |                     |           |                  |           |                |           |
| Log$_2$-transformed suPAR (per 1-SD) | 1.72 (1.60–1.85) | $<0.001$ | 1.61 (1.41–1.83) | $<0.001$ | 1.83 (1.67–2.00) | $<0.011$ |
| Median suPAR | 2.63 (2.20, 3.16) | $<0.001$ | 1.91 (1.41, 2.59) | $<0.001$ | 3.07 (2.45, 3.84) | $<0.001$ |
| suPAR quartile I | Referent | | Referent | | Referent |
| suPAR quartile II | 1.20 (0.89, 1.62) | 0.242 | 0.67 (0.40, 1.12) | 0.129 | 1.49 (1.03, 2.18) | 0.037 |
| suPAR quartile III | 2.37 (1.80, 3.12) | $<0.001$ | 1.24 (0.79, 1.96) | 0.348 | 3.07 (2.17, 4.34) | $<0.001$ |
| suPAR quartile IV | 3.87 (2.93, 5.12) | $<0.001$ | 1.76 (1.13, 2.74) | 0.013 | 5.64 (3.96, 8.03) | $<0.001$ |
| **Cardiovascular death/MI**$^T$ |                     |           |                  |           |                |           |
| Log$_2$-transformed suPAR (per 1-SD) | 1.57 (1.44–1.71) | $<0.001$ | 1.59 (1.38–1.85) | $<0.01$ | 1.59 (1.43–1.77) | $<0.001$ |
| Median suPAR | 2.23 (1.82, 2.73) | $<0.001$ | 1.84 (1.30, 2.61) | 0.001 | 2.43 (1.89, 3.12) | $<0.001$ |
| suPAR quartile I | Referent | | Referent | | Referent |
| suPAR quartile II | 1.09 (0.78, 1.52) | 0.597 | 0.93 (0.52, 1.69) | 0.822 | 1.11 (0.75, 1.65) | 0.601 |
| suPAR quartile III | 1.97 (1.46, 2.65) | $<0.001$ | 1.37 (0.79, 2.38) | 0.266 | 2.23 (1.56, 3.19) | $<0.001$ |
| suPAR quartile IV | 2.97 (2.19, 4.04) | $<0.001$ | 2.18 (1.27, 3.73) | 0.005 | 3.25 (2.24, 4.73) | $<0.001$ |

Plasma suPAR level stratified by median (2930 pg/mL) and quartile (2275, 2930, and 3929 pg/mL) levels in the overall EmCAB cohort. Cox proportional hazards regression models adjusted for sex, age, race, diabetes mellitus, current smoking, hypertension, body mass index, estimated glomerular filtration rate, history of coronary artery bypass graft, heart failure, peripheral artery disease, acute MI at enrollment, revascularization at enrollment, and cardiovascular medication (angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker, aspirin, β-blocker, clopidogrel, and statin) use. EmCAB indicates Emory Cardiovascular Biobank; HR, hazard ratio; MI, myocardial infarction; suPAR, soluble urokinase-type plasminogen activator receptor.

$^*$The multiplicative interaction of sex with log$_2$-transformed suPAR ($P = 0.005$), median suPAR ($P = 0.007$) and suPAR quartiles ($P = 0.001$) was significant for all-cause mortality in the overall cohort.

$^T$The multiplicative interaction of sex with log$_2$-transformed suPAR ($P = 0.037$) was significant, with median suPAR ($P = 0.061$) was nominal; and with suPAR quartiles ($P = 0.182$) was not significant for cardiovascular death/MI in the overall cohort.

DOI: 10.1161/JAHA.119.015457
The Kaplan–Meier survival curves with the respective sex-specific cutoffs for all-cause mortality and cardiovascular death/MI are depicted in Figure 2A and 2B, respectively. Women and men with plasma suPAR levels above the respective sex-specific cutoffs had a similar incidence of all-cause mortality (38.5% for women and 35.5% for men), whereas in men, the increase in risk began at levels above the sixth decile (>2918 pg/mL). The incidence of adverse outcomes among both men and women was similar at the highest sex-specific suPAR levels (deciles 9 and 10). MI indicates myocardial infarction; suPAR, soluble urokinase-type plasminogen activator receptor.

**Figure 1.** Cumulative incidence of adverse outcomes across sex-specific suPAR deciles. Sex-specific cumulative incidence of all-cause mortality (A) and cardiovascular death/nonfatal MI events (B) across deciles of plasma suPAR levels. The cumulative incidence of adverse outcomes across increased sex-specific suPAR deciles, but the progressive increase in women occurred in those above the fifth decile, whereas in men, the increase in risk began at levels above the sixth decile (>2918 pg/mL). The incidence of adverse outcomes among both men and women was similar at the highest sex-specific suPAR levels (deciles 9 and 10). MI indicates myocardial infarction; suPAR, soluble urokinase-type plasminogen activator receptor.

| Women (median suPAR) | Decile 1 | Decile 2 | Decile 3 | Decile 4 | Decile 5 | Decile 6 | Decile 7 | Decile 8 | Decile 9 | Decile 10 |
|----------------------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| 1760                 | 2167    | 2503    | 2768    | 3059    | 3414    | 3793    | 4205    | 5223    | 7491    |          |
| (Events/N)           | 11/154  | 20/154  | 16/155  | 12/154  | 31/153  | 28/154  | 26/155  | 34/154  | 49/155  | 74/154  |
| Men (median suPAR)   | 1606    | 1938    | 2184    | 2406    | 2635    | 2918    | 3222    | 3641    | 4431    | 6403    |
| (Events/N)           | 15/262  | 16/266  | 14/264  | 27/264  | 24/265  | 42/265  | 61/264  | 74/264  | 89/264  | 132/264 |

**Figure 1.** Cumulative incidence of adverse outcomes across sex-specific suPAR deciles. Sex-specific cumulative incidence of all-cause mortality (A) and cardiovascular death/nonfatal MI events (B) across deciles of plasma suPAR levels. The cumulative incidence of adverse outcomes across increased sex-specific suPAR deciles, but the progressive increase in women occurred in those above the fifth decile, whereas in men, the increase in risk began at levels above the sixth decile (>2918 pg/mL). The incidence of adverse outcomes among both men and women was similar at the highest sex-specific suPAR levels (deciles 9 and 10). MI indicates myocardial infarction; suPAR, soluble urokinase-type plasminogen activator receptor.

| Women (median suPAR) | Decile 1 | Decile 2 | Decile 3 | Decile 4 | Decile 5 | Decile 6 | Decile 7 | Decile 8 | Decile 9 | Decile 10 |
|----------------------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| 1760                 | 2167    | 2503    | 2768    | 3059    | 3414    | 3793    | 4205    | 5223    | 7491    |          |
| (Events/N)           | 11/154  | 20/154  | 16/155  | 12/154  | 31/153  | 28/154  | 26/155  | 34/154  | 49/155  | 74/154  |
| Men (median suPAR)   | 1606    | 1938    | 2184    | 2406    | 2635    | 2918    | 3222    | 3641    | 4431    | 6403    |
| (Events/N)           | 15/262  | 16/266  | 14/264  | 27/264  | 24/265  | 42/265  | 61/264  | 74/264  | 89/264  | 132/264 |

**Figure 1.** Cumulative incidence of adverse outcomes across sex-specific suPAR deciles. Sex-specific cumulative incidence of all-cause mortality (A) and cardiovascular death/nonfatal MI events (B) across deciles of plasma suPAR levels. The cumulative incidence of adverse outcomes across increased sex-specific suPAR deciles, but the progressive increase in women occurred in those above the fifth decile, whereas in men, the increase in risk began at levels above the sixth decile (>2918 pg/mL). The incidence of adverse outcomes among both men and women was similar at the highest sex-specific suPAR levels (deciles 9 and 10). MI indicates myocardial infarction; suPAR, soluble urokinase-type plasminogen activator receptor.
**Figure 2.** Kaplan–Meier survival among men and women above or below sex-specific suPAR cutoffs. Kaplan–Meier curves for survival from all-cause mortality (A) and cardiovascular death/nonfatal MI events (B) among men and women above or below the respective sex-specific suPAR cutoffs. The sex-specific suPAR cutoffs for all-cause mortality were 4392 pg/mL for women (76th percentile) and 3187 pg/mL for men (64th percentile). The corresponding cutoffs for cardiovascular death/MI events were 3888 pg/mL for women (67th percentile) and 2941 pg/mL for men (56th percentile). MI indicates myocardial infarction; suPAR, soluble urokinase-type plasminogen activator receptor.
for men, $P=0.3$) and cardiovascular death/MI (24.9% for women and 23.5% for men, $P=0.6$).

**Discussion**

We investigated the determinants and implications of sex-based differences in plasma suPAR levels and the impact of sex on the prognostic value of suPAR in patients with CAD. First, both asymptomatic women and those with CAD have 10% to 12% higher circulating suPAR levels compared with men after adjusting for potential confounders. Second, higher body fat and an increasing visceral fat distribution in women are at least partly responsible for the higher suPAR levels. Third, elevated suPAR levels have a similar association with adverse cardiovascular outcomes in both women and men with CAD when sex-specific suPAR cutoff values are utilized.

**Sex and suPAR Levels**

It is well established that women have higher levels of inflammatory markers including hsCRP, IL-6, serum amyloid A, D-dimer, and lipoprotein phospholipase A2,21-23,31,32 some of which are attributed, at least partly, to visceral adiposity in women.23 Herein, we report that levels of plasma suPAR, the circulating form of uPAR, a measure of systemic inflammation and immune activation,2 are also higher in women, even after adjusting for demographics, risk factors, medication use, and systemic inflammation measured as circulating hsCRP levels. Previous studies have shown that visceral adiposity is associated with higher suPAR levels,33,34 and we observed that the association of female sex with suPAR was slightly attenuated but remained significant after adjusting for visceral adiposity measures.

**Impact of Sex on the Association of suPAR With Adverse Outcomes**

Elevated plasma suPAR levels are associated with risk of adverse cardiovascular and renal outcomes in the general population and among patients with established cardiovascular disease.19,35-37 Prior work from our group has additionally shown that the association of suPAR with outcomes is independent of other biomarkers including fibrin degradation products, heat shock protein-70, and very importantly, hsCRP levels.39

Our observations regarding the impact of sex on the association of suPAR with adverse outcomes are similar to healthy Danish participants in the MONICA (Monitoring trends and determinants of cardiovascular disease) study where the hazard ratio of the top tertile was 1.7 in women compared with 2.1 for men using the same cut-off value.19 Herein we demonstrate, using sex-specific suPAR deciles, that the incidence of cardiovascular events was similarly elevated in both men and women at the highest levels. Lastly, we observed significant overlap between survival curves for women and men above or below the derived sex-specific cutoff values. Overall, these findings suggest that elevated plasma suPAR levels have a similar association with adverse cardiovascular events among both men and women when sex-specific levels are utilized.

**Clinical Implications**

Our findings regarding the association of sex with suPAR levels and the impact of sex on the association of suPAR with adverse outcomes have important implications for future research focused on leveraging biomarkers to improve cardiovascular risk assessment. The Reynold’s risk score exemplifies this potential clinical application and incorporates hsCRP into the primary prevention risk assessment algorithm. Since sex is a predictor of hsCRP levels and impacts the association of hsCRP with outcomes, sex-specific Reynold’s risk score equations have been created.39,40 As the evidence base for the clinical applicability of suPAR grows, similar sex-specific algorithms will be necessary for using suPAR.

**Strengths and Limitations**

Strengths of our study include analysis of 2 large, clinically and ethnically diverse cohorts. The primary prevention cohort underwent extensive phenotyping, including visceral fat distribution studies, and provided important mechanistic insights regarding sex differences. Patients with CAD validated the observed sex differences in suPAR levels, and these patients were followed for adjudicated outcomes in order to develop sex-specific suPAR cutoff values for secondary risk assessment. However, the suPAR cutoff values determined in our study cannot necessarily be extrapolated to the general population. We have not evaluated the impact of change in cardioprotective medications over time in this study, although our data suggest that suPAR values were lower in patients with CAD treated with statins. Lastly, we cannot exclude the possibility of residual confounding explaining the relationship between sex, suPAR levels, and adverse outcomes in CAD, given the observational nature of this study.

**Conclusions**

Women with and without CAD have 10% to 12% higher plasma suPAR levels compared with men. An elevated suPAR level is equally predictive of an increased risk of adverse
cardiovascular events in women and men, when sex-specific levels are utilized.

Acknowledgments

The authors would like to acknowledge the Emory Cardiovascular Biobank participants and research study coordinators.

Author contributions: Mehta contributed to the conception or design of the work. Desai, Ko, Liu, Dhindsa, Nayak, Hooda, Martini, Ejaz, Sperling, Reiser, Hayek, and Quyyumi contributed to the acquisition, analysis, or interpretation of data for the work. Mehta, Desai and Quyyumi drafted the manuscript. Ko, Liu, Dhindsa, Nayak, Hooda, Martini, Ejaz, Sperling, Reiser, and Hayek critically revised the manuscript. All gave final approval and agree to be accountable for all aspects of work ensuring integrity and accuracy.

Sources of Funding

Mehta is supported by American Heart Association grant 19POST34400057 and Abraham J. & Phyllis Katz Foundation. Quyyumi is supported by NIH grants 1P20HL113451-01, 1R61HL138657-02, 1P30DK111024-03S1, 5R01HL095479-08, 3RF1AG051633-01S2, 5RO1AG042127-06, 2P01HL086773-3-08, U54AG062334-01, 1R01HL141205-01, 5P01HL101399-02, 1P20HL113451-01, 5P01HL086773-09, 1RF1AG051633-01, R01 NS064162-01, R01 HL8650-01, HL095479-01, 1DP3DK094346-01, 2P01HL086773, and American Heart Association grant 15SFCRN23910003.

Disclosures

Reiser is co-founder and stockholder of Trisaq, a biopharma-ceutical company that targets suPAR. The remaining authors have no disclosures to report.

References

1. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FN, Djousse L, Egan MSV, Ferguson JF, Forata N, Jordan LC, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsy PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, O’Mahony H, Pandey A, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satish GM, Schroeder EB, Shah SH, Spartanio NL, Stokes A, Tirschwell DL, Tsao CW, Turakhia MP, VanWagner LB, Wilkins JT, Wong SS, Virani SS. American Heart Association Council on Epidemiology, Prevention Statistics Committee, Stroke Statistics Sub-committee. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 2019;139:e56–e528.

2. Papezi MF, Hoes AW, Agewall S, Albuc B, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Lochan ML, Lofflent H, Marques-Vidal P, Perk J, Prescot E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S, ESC Scientific Development Group. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315–2381.

3. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberg ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Munoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yobsoh J, Ziese B. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation. 2019;140:e596–e646.

4. Bohula EA, Bonaca MP, Braunwald E, Aylward PE, Corbalan R, De Ferrari GM, He P, Lewis BS, Merlindi PA, Murphy SA, Sabatine MS, Scirica BM, Morrow DA. Atherothrombotic risk stratification and the efficacy and safety of vorapaxar in patients with stable ischemic heart disease and previous myocardial infarction. Circulation. 2016;134:303–313.

5. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109:II–110.

6. Eapen DJ, Manocha P, Patel RS, hammadah M, Veledar E, Wessel C, Nanjundappa RA, Sikora S, Malayter D, Wilson PW, Sperling L, Quyyumi AA, Epstein SE. Aggregate risk score based on markers of inflammation, cell stress, and coagulation is an independent predictor of adverse cardiovascular outcomes. J Am Coll Cardiol. 2013;62:329–337.

7. Hamie L, Daoud G, Nemer G, Nammour T, El Chediak A, Uthman IW, Kibbi AG, Aeid E, Kurbian M. SuPAR, an emerging biomarker in kidney and inflammatory diseases. Postgrad Med J. 2018;94:517–524.

8. Huai G, Mazar AP, Kuo A, Perry GG, Shaw DE, Callahan J, Li Y, Yuan C, Bian C, Chen L, Furie B, Furie BC, Cines DB, Huang M. Structure of human urokinase plasminogen activator in complex with its receptor. Science. 2006;311:656–659.

9. Wei C, Moller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Munder P, Reiser J. Modification of kidney barrier function by the urokinase receptor. Nat Med. 2008;14:55–63.

10. Quyyumi AA, Al-Kassem H, Gagnon P. Regulation of urokinase receptor function in atherothrombotic disease. Thromb Haemost. 2002;88:295–301.

11. Mondino A, Blasi F, suPAR and in fibrinolysis, immunity and pathology. Trends Immunol. 2004;25:450–455.

12. Selleri C, Montuori N, Salvati A, Serio B, Pesapane A, Ricci P, Gorrasi A, Li Santi A, Hoyer-Hansen G, Ragno P. Involvement of urokinase receptor in the cross-talk between human hematopoietic stem cells and bone marrow microenvironment. Oncotarget. 2016;7:60206–60217.

13. van Veen M, Matas-Rico E, van de Wetering K, Leyton-Puig D, Kedziora KM, De Lorenzi V, Szijf-Buttsma Y, van den Broek B, Jalink K, Sidenius N, Perrakis A, Moolenaar WH. Negative regulation of urokinase receptor activity by a GPI-specific phospholipase C in breast cancer cells. Cell. 2017;6:e23649.

14. Tahh M, Wei C, Fernandez I, Li J, Tardi NJ, Tracy M, Wadhwani S, Cao Y, Peev V, Zloza A, Luschiks J, Hayek SS, O’Connor C, Bitzer M, Gupta V, Sever S, Sykes DB, Scadden DT, Reiser J. Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proinflammatory disease. Nat Med. 2017;23:100–106.

15. Mekonnen G, Corban MT, Hung OY, Eapen DJ, Al-Kassem H, Rasoul-Arzrumly E, McDaniel MC, Pleak T, Thorball CW, Sperling L, Quyyumi AA, Samady H. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease. Atherosclerosis. 2015;239:55–60.

16. Nakanishi K, Fukuda S, Shimada K, Miyazaki C, Otsuka K, Maeda K, Miyahana R, Kawarabayashi T, Watanabe H, Yoshikawa J, Yoshimaya M. Impaired coronary flow reserve as a marker of microvascular dysfunction to predict long-term cardiovascular outcomes, acute coronary syndrome and the development of heart failure. Circ J. 2012;76:1958–1964.

17. Sorensen MH, Gerke O, Eugen-Olsen J, Munkholm H, LambrechtSEN J, Sand NP, Mickleh H, Rasmussen LM, Olsen MH, Diederichsen A. Soluble urokinase plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease. Atherosclerosis. 2014;237:63–70.

18. Lyngbaek S, Marott JL, Moller DV, Christiansen M, Iversen KK, Clemmensen E, Stokke E, Sorensen MH, Gerke O, Eugen-Olsen J, Hansen PR. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention. Am J Cardiol. 2012;110:1756–1763.

19. Lyngbaek S, Marott JL, Sehestedt T, Hansen TW, Olsen MH, Andersen O, Linneberg A, Haugaa SB, Eugen-Olsen J, Hansen PR, Jeppesen J. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score. Int J Cardiol. 2013;167:2904–2911.
receptor in elective coronary artery bypass graft surgery patients and cardiopulmonary bypass use. PLoS One. 2014;9:e89293.

21. Thorand B, Baumert J, Doring A, Herder C, Kolb H, Rathmann W, Gianì G, Koenig W, Group K. Sex differences in the relation of body composition to markers of inflammation. Atherosclerosis. 2006;184:216–224.

22. Khera A, Vega GL, Das SR, Ayers C, McGuire DK, Grundy SM, de Lemos JA. Sex differences in the relationship between C-reactive protein and body fat. J Clin Endocrinol Metab. 2009;94:3251–3258.

23. Lew J, Sanghavi M, Ayers CR, McGuire DK, Omland T, Atzler D, Gore MO, Neeland I, Berry JD, Khera A, Rohatgi A, de Lemos JA. Sex-based differences in cardiometabolic biomarkers. Circulation. 2017;135:544–555.

24. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, Petersen J, Pielak T, Moller LN, Jeppesen J, Lyngbaek S, Fenger M, Olsen MH, Hildebrandt PR, Borch-Johnsen K, Jorgensen T, Haugaard SA. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med. 2010;268:296–308.

25. Tabassum R, Cunningham L, Stephens EH, Sturdivant K, Martin GS, Brigham KL, Gibson G. A longitudinal study of health improvement in the Atlanta CHDWB wellness cohort. J Pers Med. 2014;4:489–507.

26. Brigham KL. Predictive health: the imminent revolution in health care. J Am Geriatr Soc. 2010;58(suppl 2):S298–S302.

27. Ko YA, Hayek S, Sandesara P, Samman Tahhan A, Quyyumi A. Cohort profile: the Emory Cardiovascular Biobank (EmCAB). BMJ Open. 2017;7:e017853.

28. Hayek SS, Sever S, Ko YA, Trachtman H, Awad M, Wadhwani S, Attitans MM, Wei C, Hutton AL, French AL, Sperling LS, Lerakis S, Quyyumi AA, Reiser J. Soluble urokinase receptor and chronic kidney disease. N Engl J Med. 2015;373:1916–1925.

29. Patel RS, Ghasemzadeh N, Eapen DJ, Sher S, Arshad S, Ko YA, Veledar E, Samady H, Sperling L, Vaccarino V, Jones DP, Sperling LS, Lerakis S, Quyyumi AA. Soluble urokinase plasminogen activator receptor improves risk prediction in patients with chronic heart failure. JACC Heart Fail. 2017;5:268–277.

30. Samman Tahhan A, Hayek SS, Sandesara P, Hajiari J, Hammadah M, O’Neal WT, Kelli HM, Alkhoder A, Ghasemzadeh N, Ko YA, Aida H, Gafeer MM, Abdelhadi N, Mohammed KH, Patel K, Arya S, Reiser J, Vaccarino V, Sperling L, Quyyumi A. Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes. Atherosclerosis. 2017;264:108–114.

31. Ghasemzadeh N, Hayek SS, Ko YA, Eapen DJ, Patel RS, Manocha P, Al Kassem H, Khayata M, Veledar E, Kremaistinos DT, Lerakis S, Sperling L, Quyyumi AA. Soluble urokinase-type plasminogen activator receptor improves risk prediction in patients with myocardial infarction. 2012;33:2551–2567.

32. O'Connor MF, Motivala SJ, Valladares EM, Olmstead R, Irwin MR. Sex differences in monocyte expression of IL-6: role of autonomic mechanisms. Am J Physiol Regul Integr Comp Physiol. 2007;293:R145–R151.

33. Sjoholm K, Lundgren M, Olsson M, Eriksson JW. Association of serum amyloid A levels with adipocyte size and serum levels of adipokines: differences between men and women. Cytokine. 2009;48:260–266.

34. Sjoholm K, Lundgren M, Olsson M, Eriksson JW. Association of serum amyloid A levels with adipocyte size and serum levels of adipokines: differences between men and women. Cytokine. 2009;48:260–266.

35. Eapen DJ, Manocha P, Ghasemzadeh N, Patel RS, Al Kassem H, Hammadah M, Veledar E, Le NA, Pielak T, Thorball CW, Velegraki A, Kremaistinos DT, Lerakis S, Sperling L, Quyyumi AA. Soluble urokinase plasminogen activator receptor levels is an independent predictor of the presence and severity of coronary artery disease and of future adverse events. J Am Heart Assoc. 2014;3:e001118. DOI: 10.1161/JAHA.114.001118.

36. Koller L, Stojkovic S, Richter B, Sulzgruber P, Potolidis C, Liebhart F, Mortl D, Berger R, Goliash G, Wojta J, Hulsman M, Niessen A. Soluble urokinase-type plasminogen activator receptor improves risk prediction in patients with chronic heart failure. JACC Heart Fail. 2017;5:268–277.

37. Samman Tahhan A, Hayek SS, Sandesara P, Hajiari J, Hammadah M, O’Neal WT, Kelli HM, Alkhoder A, Ghasemzadeh N, Ko YA, Aida H, Gafeer MM, Abdelhadi N, Mohammed KH, Patel K, Arya S, Reiser J, Vaccarino V, Sperling L, Quyyumi A. Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes. Atherosclerosis. 2017;264:108–114.

38. Ghasemzadeh N, Hayek SS, Ko YA, Eapen DJ, Patel RS, Manocha P, Al Kassem H, Khayata M, Veledar E, Kremaistinos DT, Thorball CW, Pielak T, Sikorsa S, Zafari AM, Lerakis S, Sperling L, Vaccarino V, Jones DP, Sperling L, Quyyumi AA. Soluble urokinase-type plasminogen activator receptor improves risk prediction in patients with myocardial infarction. 2012;33:2551–2567.

39. O’Connor MF, Motivala SJ, Valladares EM, Olmstead R, Irwin MR. Sex differences in monocyte expression of IL-6: role of autonomic mechanisms. Am J Physiol Regul Integr Comp Physiol. 2007;293:R145–R151.
SUPPLEMENTAL MATERIAL
Data S1.

Study Population

The Emory Center for Health Discovery and Wellbeing (CHDWB) was established in 2008 as an initiative aiming towards the prevention of the chronic diseases through promotion of a healthy lifestyle in employees of Emory University and Georgia Institute of Technology, Atlanta, Georgia, USA. (1) Our analysis includes 666 unique participants without known CAD that had plasma suPAR measured at the time of enrollment. Subjects with an acute illness, recent hospitalization within the year prior to enrollment, pregnant women, and individuals with poorly controlled medical comorbidities were excluded.

The Emory Cardiovascular Biobank (EmCAB) is an ongoing prospective registry of patients undergoing cardiac catheterization for evaluation of CAD at three Emory Healthcare affiliated hospitals. (2) Our study includes participants enrolled between 2003 and 2015. Within the EmCAB cohort, there were 4,184 unique participants who underwent plasma suPAR measurement at enrollment and were followed for adverse outcomes. We excluded patients with active cancer, organ transplantation, severe valvular heart disease, and missing follow-up.

Cardiovascular risk factors

Participants in both cohorts were interviewed to obtain information about demographic characteristics, medical history, medication use, and behavioral habits. In the CHDWB cohort, physical measurements included vital signs, height, weight, and body mass index (BMI) calculated as weight (in kilograms) divided by height (in meters)-squared. Hypertension, hypercholesterolemia, and diabetes mellitus were defined according to the Joint National Committee, Adult Treatment Panel III, and American Diabetes Association criteria, respectively,
and smoking habits were recorded and classified as nonsmoker or ever smoker if there was a lifetime history of smoking at least 100 cigarettes. Fasting blood samples were collected for a lipid profile, metabolic panel, and hsCRP measurement (Quest Diagnostics, Madison, NJ, USA). Estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI equation. Lastly, body fat composition was measured as fat mass and android-to-gynoid fat ratio using dual-energy x-ray absorptiometry (iDXA, GE Lunar Densitometry, General Electric Company, Boston, MA, USA), which is considered a gold standard measure for the identification of whole-body fat mass within a 2% coefficient of variation. The android region included an area from the top of the iliac crest to 20% of the distance from the iliac crest to the bottom of the subject’s head. The gynoid region extended from the top of the greater trochanter down a distance twice the height of the android region. Overall, 10.5% and 6.5% participants had data missing for hsCRP and visceral adiposity measures in the cohort. This data was assumed to be missing at random and was imputed using the Visualization and Imputation of Missing values (VIM) R package by utilizing the k-nearest neighbors approach.

In the EmCAB cohort, the prevalence of hypertension, hyperlipidemia, and diabetes was determined by physician diagnosis and/or treatment. Medical records and International Classification of Diseases-9 (ICD-9) codes were reviewed to confirm participant-reported medical history. Previous history of coronary artery bypass grafting (CABG), heart failure, peripheral artery disease, and the presence of an acute myocardial infarction and revascularization of any coronary artery at time of enrollment were recorded. The use of angiotensin converting enzyme inhibitor (ACEi)/angiotensin-II receptor blocker (ARB), aspirin, beta blocker, clopidogrel, and statin was recorded as well.
Table S1. Baseline characteristics of EmCAB participants overall and stratified by sex.

| Participant Characteristics                  | Overall (n=4,184) | Women (n=1,544) | Men (n=2,640) | p-value |
|----------------------------------------------|-------------------|-----------------|---------------|---------|
| Age, years (SD)                              | 63.1 (12.2)       | 63.9 (12.7)     | 62.7 (11.8)   | 0.003   |
| Black race (%)                               | 924 (22.1)        | 454 (29.4)      | 470 (17.8)    | < 0.001 |
| Diabetes (%)                                 | 1,411 (33.9)      | 512 (33.3)      | 899 (34.2)    | 0.564   |
| Hypertension (%)                             | 3,233 (77.6)      | 1219 (79.4)     | 2014 (76.6)   | 0.051   |
| Current smoking (%)                          | 347 (8.3)         | 120 (7.8)       | 227 (8.6)     | 0.384   |
| eGFR, ml/min/1.73 m² (SD)                    | 73.0 (24.6)       | 71.9 (25.9)     | 73.7 (23.8)   | 0.030   |
| Body mass index, kg/m² (SD)                  | 29.9 (6.4)        | 30.4 (7.6)      | 29.6 (5.6)    | < 0.001 |
| History of CABG (%)                          | 977 (23.4)        | 231 (15.0)      | 746 (28.3)    | < 0.001 |
| History of Heart Failure (%)                 | 1,314 (31.4)      | 479 (31.0)      | 835 (31.6)    | 0.704   |
| History of Peripheral Artery Disease (%)     | 683 (16.3)        | 239 (15.5)      | 444 (16.8)    | 0.260   |
| Acute MI at enrollment (%)                   | 361 (8.6)         | 123 (8.0)       | 238 (9.0)     | 0.254   |
| Revascularization at enrollment (%)          | 2,161 (51.6)      | 629 (40.7)      | 1532 (58.0)   | < 0.001 |
| Aspirin use (%)                              | 3,180 (76.0)      | 1084 (70.2)     | 2096 (79.4)   | < 0.001 |
| Clopidogrel use (%)                          | 1,862 (44.5)      | 568 (36.8)      | 1294 (49.0)   | < 0.001 |
| ACEi/ARB* use (%)                            | 2,371 (56.7)      | 813 (52.7)      | 1558 (59.0)   | < 0.001 |
| Beta blocker use (%)                         | 2,833 (67.7)      | 1001 (64.8)     | 1832 (69.4)   | 0.003   |
| Statin use (%)                               | 2,972 (71.0)      | 1005 (65.1)     | 1967 (74.5)   | < 0.001 |
| hsCRP, mg/L                                  | 2.8 [1.1, 7.3]    | 3.7 [1.5, 9.0]  | 2.4 [1.0, 6.2]| < 0.001 |
| suPAR, pg/ml                                 | 2,930 [2,275-3,929]| 3,245 [2,503-4,295]| 2,761 [2,183-3,641]| < 0.001 |
| Death (%)                                    | 795 (19.0)        | 301 (19.5)      | 494 (18.7)    | 0.540   |
| Cardiovascular death/nonfatal MI (%)         | 604 (14.4)        | 226 (14.6)      | 378 (14.3)    | 0.785   |
EmCAB, Emory Cardiovascular Biobank; eGFR, estimated glomerular filtration rate; CABG, coronary artery bypass graft; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; hsCRP, high-sensitivity C-reactive protein; suPAR, soluble urokinase-type plasminogen activating receptor; MI, myocardial infarction. Continuous variables are presented as mean (SD) or median [25-75th percentile] and categorical variables are presented as count (proportion). hsCRP measured in 3,645 participants (1,336 women and 2,309 men).
Table S2. Independent association of female sex with plasma suPAR levels among EmCAB participants.

| Model         | Estimate (95% CI) | p-value |
|---------------|-------------------|---------|
| Unadjusted    | 13.6% (11.4%, 15.9%) | < 0.001 |
| Model 1†      | 12.0% (10.0%, 16.1%) | < 0.001 |
| Model 2‡      | 11.7% (9.5%, 13.9%)  | < 0.001 |

suPAR, soluble urokinase-type plasminogen receptor activator; EmCAB, Emory Cardiovascular Biobank. †Adjusted for covariates including age, race, diabetes, current smoking, hypertension, body mass index, estimated glomerular filtration rate, history of coronary artery bypass graft, heart failure, peripheral artery disease, acute MI at enrollment, revascularization at enrollment, and cardiovascular medication (Angiotensin-converting enzyme inhibitor/Angiotensin II receptor blocker, aspirin, beta blocker, clopidogrel, and statin) use. ‡Model 2 adjusted for covariates included in Model 1 and log-transformed high-sensitivity C-reactive protein. High-sensitivity C-reactive protein measured in 3,645 participants (1,336 women, 2,309 men).
Table S3. Sex-specific independent predictors of plasma suPAR levels among CHDWB participants.

| Characteristic                              | Women          |       | Men            |       |
|---------------------------------------------|----------------|-------|----------------|-------|
|                                             | Beta-estimate  | p-value | Beta-estimate  | p-value |
|                                             | (95% CI)       |        | (95% CI)       |        |
| Age (per year)                              | 0.000 (-0.005, 0.005) | 0.966 | 0.012 (0.006, 0.018) | < 0.001 |
| Black race                                  | -0.002 (-0.092, 0.087) | 0.957 | -0.035 (-0.229, 0.160) | 0.726  |
| Diabetes                                    | 0.123 (0.006, 0.239) | 0.039 | 0.129 (-0.061, 0.318) | 0.184  |
| Antihypertensive use                        | 0.075 (-0.014, 0.165) | 0.098 | 0.036 (-0.098, 0.170) | 0.602  |
| Systolic blood pressure (per mmHg)          | 0.002 (-0.001, 0.004) | 0.238 | 0.000 (-0.004, 0.004) | 0.862  |
| Current smoking                             | 0.111 (-0.060, 0.282) | 0.203 | 0.068 (-0.119, 0.255) | 0.477  |
| Total cholesterol†                          | 0.096 (-0.118, 0.310) | 0.379 | -0.189 (-0.497, 0.119) | 0.228  |
| HDL-cholesterol†                            | -0.234 (-0.394, -0.074) | 0.004 | -0.096 (-0.340, 0.148) | 0.439  |
| eGFR † (per 10 ml/min/1.73 m²)              | -0.004 (-0.007, -0.001) | 0.004 | -0.001 (-0.005, 0.004) | 0.802  |
| Body mass index†                            | 0.010 (-0.354, 0.374) | 0.957 | -0.020 (-0.746, 0.707) | 0.958  |
| Body fat mass†                              | 0.325 (0.119, 0.531) | 0.002 | 0.004 (-0.279, 0.287) | 0.976  |
| Android-to-gynoid fat ratio†                | -0.175 (-0.329, -0.021) | 0.026 | 0.052 (-0.298, 0.195) | 0.682  |
| Statin use                                  | -0.038 (-0.180, 0.104) | 0.599 | -0.176 (-0.313, -0.039) | 0.012  |
| hsCRP ††                                   | -0.026 (-0.066, 0.014) | 0.202 | 0.040 (-0.026, 0.105) | 0.239  |
| Estradiol‡                                  | 0.028 (-0.016, 0.071) | 0.210 | -             | -      |
| Total testosterone‡                         | -               | -     | -0.041 (-0.172, 0.091) | 0.542  |

suPAR, soluble urokinase-type plasminogen activator receptor; CHDWB, Emory Center for Health Discovery and Wellbeing; HDL, high-density lipoprotein; eGFR, estimated glomerular filtration rate; hsCRP, high-sensitivity C-reactive protein. †Values were log-
transformed before analysis. Estradiol and testosterone levels available in 383 women and 197 men, respectively, and log-transformed before analysis.
Table S4. Sex-specific independent predictors of plasma suPAR levels among EmCAB participants.

| Characteristic                              | Women Beta-estimate (95% CI) | p-value | Men Beta-estimate (95% CI) | p-value |
|---------------------------------------------|------------------------------|---------|---------------------------|---------|
| Age                                         | -0.001 (-0.003, 0.002)       | 0.657   | 0.000 (-0.002, 0.002)     | 0.780   |
| Black race                                  | 0.007 (-0.055, 0.070)        | 0.821   | 0.013 (-0.068, 0.219)     | 0.640   |
| Diabetes mellitus                           | 0.185 (0.124, 0.245)         | < 0.001 | 0.152 (0.108, 0.197)      | < 0.001 |
| Hypertension                                | 0.024 (-0.048, 0.096)        | 0.513   | 0.000 (-0.049, 0.050)     | 0.986   |
| Current smoking                             | 0.112 (0.010, 0.215)         | 0.032   | 0.224 (0.151, 0.298)      | < 0.001 |
| History of CABG                             | 0.082 (0.003, 0.160)         | 0.041   | 0.022 (-0.026, 0.069)     | 0.373   |
| History of Heart Failure                    | 0.097 (0.035, 0.158)         | 0.002   | 0.107 (0.062, 0.152)      | < 0.001 |
| History of Peripheral Artery Disease        | 0.104 (0.025, 0.183)         | 0.010   | 0.130 (0.070, 0.186)      | < 0.001 |
| Acute MI at enrollment                      | -0.008 (-0.111, 0.094)       | 0.872   | -0.008 (-0.065, 0.081)    | 0.827   |
| Revascularization at enrollment             | 0.019 (-0.052, 0.090)        | 0.596   | -0.037 (-0.085, 0.011)    | 0.128   |
| Body mass index (per kg/m$^2$)              | 0.006 (0.002, 0.010)         | 0.002   | 0.002 (-0.002, 0.005)     | 0.431   |
| eGFR‡ (per 10 ml/min/1.73 m$^2$)             | -0.011 (-0.013, -0.010)      | < 0.001 | -0.012 (-0.013, -0.011)   | < 0.001 |
| ACEi/ARB use                                | 0.016 (-0.043, 0.076)        | 0.592   | 0.004 (-0.041, 0.048)     | 0.878   |
| Aspirin use                                 | -0.037 (-0.107, 0.034)       | 0.311   | -0.066 (-0.126, -0.007)   | 0.028   |
| Beta blocker use                            | 0.016 (-0.049, 0.080)        | 0.635   | 0.058 (0.009, 0.108)      | 0.020   |
| Clopidogrel use                              | 0.058 (-0.011, 0.127)        | 0.102   | -0.013 (-0.063, 0.037)    | 0.618   |
| Statin use                                  | -0.128 (-0.195, -0.061)      | < 0.001 | -0.059 (-0.114, -0.003)   | 0.039   |
| hsCRP‡                                      | 0.046 (0.029, 0.063)         | < 0.001 | 0.042 (0.029, 0.054)      | < 0.001 |
suPAR, soluble urokinase-type plasminogen activator receptor; EmCAB, Emory Cardiovascular Biobank; CABG, coronary artery bypass graft; MI, myocardial infarction; eGFR, estimated glomerular filtration rate; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; hsCRP, high-sensitivity C-reactive protein. †High-sensitivity CRP measured in 3,645 participants (1,336 women and 2,309 men) and log-transformed before analysis.
SUPPLEMENTAL REFERENCES:

1. Brigham KL. Predictive health: the imminent revolution in health care. *J Am Geriatr Soc.* 2010;58 Suppl 2:S298-302.
2. Ko YA, Hayek S, Sandesara P, Samman Tahhan A, Quyyumi A. Cohort profile: the Emory Cardiovascular Biobank (EmCAB). *BMJ Open.* 2017;7:e018753.
3. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD EPI. A new equation to estimate glomerular filtration rate. *Ann Intern Med.* 2009;150:604-12.
4. Kelli HM, Corrigan FE, 3rd, Heinl RE, Dhindsa DS, Hammadah M, Samman-Tahhan A, Sandesara P, O'Neal WT, Al Mheid I, Ko YA, Vaccarino V, Ziegler TR, Sperling LS, Brigham K, Jones D, Martin GS, Quyyumi AA. Relation of Changes in Body Fat Distribution to Oxidative Stress. *Am J Cardiol.* 2017;120:2289-93.
5. Xu W, Chafi H, Guo B, Heymsfield SB, Murray KB, Zheng J, Jia G. Quantitative Comparison of 2 Dual-Energy X-ray Absorptiometry Systems in Assessing Body Composition and Bone Mineral Measurements. *J Clin Densitom.* 2016;19:298-304.
6. Kowarik A, Templ M. Imputation with the R Package VIM. *J Stat Softw.* 2016;74.